New Kids on the Block: pipeline, approvals, and reimbursement
This activity will provide Vizient members with the most current information on newly approved medications and emerging drug therapies, including clinical implications. This activity will also include strategies that can be used to charge appropriately for new medications and how facilities will be reimbursed.
Target Audience
Pharmacists and Pharmacy Technicians
Learning Objectives
Learning objectives
- Identify impactful pipeline medications and discuss the Vizient process for monitoring the pipeline.
- Review recent medication approvals with significant clinical impact.
- Evaluate reimbursement from Centers for Medicare and Medicaid Services for new medications.
Pharmacy technician learning objectives
- Identify impactful pipeline medications and discuss the Vizient process for monitoring the pipeline.
Additional Information
Attachment | Size |
---|---|
Helpful Tips for Users - Vizient CE System.pdf | 134.81 KB |
08-31-2022 Information for CE Credit.docx | 125.59 KB |
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
Ineligible companies – those companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
FDA Off-Label Use
Faculty presenters are also expected to disclose any discussion of (1) off-label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States.
DISCLOSURE STATEMENTS:
Absence of Relevant Financial Relationships
The following planners, faculty, and others in control of educational content have no relevant financial relationships with ineligible companies.
Off-label/unapproved drug uses or products are mentioned within this activity.
Planning committee:
Gretchen Brummel, PharmD, BCPS
Consulting Solutions Director
Vizient
Michelle Smith, PharmD, BCPS
Pharmacy Executive, MWPC Pharmacy Network
Vizient
Presenters:
Amanda Frick, PharmD, BCPS
Sr Clinical Manager
Vizient
Carolyn Liptak, MBA, RPh
Pharmacy Executive Director
Vizient
John Schoen, PharmD, BCPS
Sr. Clinical Manager of Drug Information
Vizient
Joint Accreditation Statement:
In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Designation Statement:
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-0000-22-055-L01-P and JA0006103-0000-22-055-L01-T
Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician